Search

Your search keyword '"Mestre, Ricardo"' showing total 189 results

Search Constraints

Start Over You searched for: Author "Mestre, Ricardo" Remove constraint Author: "Mestre, Ricardo"
189 results on '"Mestre, Ricardo"'

Search Results

1. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

2. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study

3. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

4. CT evaluation of lung infiltrates in the two months preceding the Coronavirus disease 19 pandemic in Canton Ticino (Switzerland): were there suspicious cases before the official first case?

5. Developing Integrated Care in Portugal Through Local Health Units

6. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

7. Antiandrogens as Therapies for COVID-19: A Systematic Review

9. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression

10. Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer

11. Mitochondrial DNA released by senescent cells triggers immunosuppression in cancer

13. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)

15. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

16. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer

17. Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.

18. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

19. sj-doc-1-tam-10.1177_17588359231156147 – Supplemental material for Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

20. Machine Learning Lifecycle for Earth Science Application: A Practical Insight into Production Deployment

23. P1245 Polymorphic Variants of HSD3B1 Gene Confer Different Outcome in Specific Subgroups of Patients Infected With SARS-CoV-2

24. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

25. Prostate Cancer and Sleep Disorders: A Systematic Review

26. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

27. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

29. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

30. Mexican Law

31. Balanced Scorecard aplicado a Unidades Hospitalares: uma revisão sistemática da literatura

32. Visualizing, Exploring, and Communicating Environmental Effects of COVID-19 Using Earth Observation Dashboard

33. The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?

34. ApoE-TREM2 axis induces pathogenic senescent-like myeloid cells in prostate cancer

36. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.

37. Clear, Consistent and Engaging: ECB Monetary Policy Communication in a Changing World

38. Inpatient hospitalizations during the first wave of COVID-19 in Portugal

46. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis

47. Percutaneous biopsy of small renal mass: can diagnostic accuracy be affected by hospital volume?

48. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer

50. Correlation between PSA kinetics and detection rate of PSMA-PET in the setting of biochemical recurrent prostate cancer: A systematic review and meta-analysis.

Catalog

Books, media, physical & digital resources